Determination of levetiracetam in human plasma by online heart-cutting liquid chromatography: Application to therapeutic drug monitoring
JOURNAL OF SEPARATION SCIENCE, vol.43, no.18, pp.3590-3596, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 43 Issue: 18
- Publication Date: 2020
- Doi Number: 10.1002/jssc.202000504
- Journal Name: JOURNAL OF SEPARATION SCIENCE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Aerospace Database, BIOSIS, CAB Abstracts, Chimica, Communication Abstracts, Compendex, EMBASE, Food Science & Technology Abstracts, INSPEC, MEDLINE, Metadex, Veterinary Science Database, Civil Engineering Abstracts
- Page Numbers: pp.3590-3596
- Keywords: human plasma, levetiracetam, online heart-cutting liquid chromatography, therapeutic drug monitoring, UV detection, TANDEM MASS-SPECTROMETRY, ANTIEPILEPTIC DRUGS, CLINICAL PHARMACOKINETICS, PERFORMANCE, VALIDATION, ACID
- Istanbul University Affiliated: Yes
Abstract
Levetiracetam is an antiepileptic drug for the treatment of psychiatric patients. In this study, a selective, straightforward, and rapid online heart-cutting liquid chromatography method was developed for the therapeutic drug monitoring of levetiracetam. This method allows for the determination of levetiracetam in human plasma without complex sample preparation. The mobile phases consisted of 30 mM aq. orthophosphoric acid solution/methanol (70:30) at a flow rate of 1 mL/min for the first system and 10 mM aq. orthophosphoric acid solution/methanol (55:45) at a flow rate of 1 mL/min for the second system. The first separation was carried out on a GL Sciences Intersil ODS-3 column (4.6 mm x 150 mm, 3 mu m) and the second separation was carried out on a Restek Ultra PFPP column (4.6 mm x 150 mm, 5 mu m). The detection was carried out at 205 nm for both systems. The method was validated for selectivity and linearity, which were in the 6-60 mu g/mL range. Intra- and interassay accuracies were <112.6%, and the intra- and interassay precisions were <6.4% for all quality control samples. The lower limit of quantitation was 6 mu g/mL. The developed method was successfully applied for therapeutic drug monitoring of plasma samples from patients.